The argument that healthpro is blatantly down ramping to buy weaker hands shares is almost as unsubstantiated and baseless as saying "Finn is up ramping so he can sell early to new/ignorant investors".
As for the capital raise, if the requisites of a "huge success" are selecting a broker that has demonstrated previously that they are going to create immediate and significant downward pressure on the company that they raised for, and the clients they connected, as well as the obvious conflict of interest from having a board member who used to work for the broker at a senior level, as well as having that broker not only understate the value proposition of the company, misspell the asset names and make claims regarding immenent debt requirements, all for only 70 odd million in an environment that is cash surplus and value poor, then I can start to understand why management got away with performance rights for a sale of Goulamina for 100m.
FFX Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
